Decrease of neurofilament is associated with reduction of clinical disease activity in glatiramer acetate treated people with multiple sclerosis

被引：0
|
作者：
Konofalska, U. [1 ]
Akgun, K. [1 ]
Proschmann, U. [1 ]
Haase, R. [2 ]
Ziemssen, T. [1 ]
机构：
[1] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[2] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P599
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [1] MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
    Casanova, Ignacio
    Dominguez-Mozo, Maria I.
    De Torres, Laura
    Aladro-Benito, Yolanda
    Garcia-Martinez, Angel
    Gomez, Patricia
    Abellan, Sara
    De Antonio, Esther
    Alvarez-Lafuente, Roberto
    BIOMEDICINES, 2023, 11 (10)
  • [2] Clinical and subclinical treatment effect is associated with serum neurofilament decrease in fingolimod treated people with multiple sclerosis
    Akguen, K.
    Holzwarth, F.
    Proschmann, U.
    Haase, R.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 522 - 523
  • [3] Clinical course of multiple sclerosis in Japanese patients treated with glatiramer acetate
    Okamoto, T.
    Lin, Y.
    Araki, M.
    Sato, W.
    Kawazoe, T.
    Wakasugi, N.
    Takewaki, D.
    Takahashi, Y.
    Yamamura, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 793 - 794
  • [4] Interferon beta and glatiramer acetate decrease oxidative activity of leukocytes in patients with multiple sclerosis
    de Riso, S.
    Angeleri, V.
    Bacchetti, T.
    Danni, M.
    Ferretti, G.
    Viti, B.
    Provinciali, L.
    MULTIPLE SCLEROSIS, 2007, 13 : S66 - S66
  • [5] Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis
    Sellebjerg, F.
    Hedegaard, C. J.
    Krakauer, M.
    Hesse, D.
    Lund, H.
    Nielsen, C. H.
    Sondergaard, H. B.
    Sorensen, P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (03) : 305 - 313
  • [6] Panniculitis in multiple sclerosis patients treated with glatiramer acetate
    Sa, J
    Cordeiro, C
    MULTIPLE SCLEROSIS, 2005, 11 : S85 - S85
  • [7] Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis
    Miravalle, Augusto
    Hendin, Barry
    Vollmer, Timothy L.
    Kala, Mrinalini
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 151 - 158
  • [8] Potential biomarkers of disease activity and response to treatment with glatiramer acetate in multiple sclerosis
    Kruszewski, Adam M.
    Rao, Gautam K.
    Tatomir, Alexandru
    Hewes, Daniel
    Tegla, Cosmin A.
    Cudrici, Cornelia D.
    Nguyen, Vingh
    Royal, Walter, III
    Bever, Christopher
    Rus, Violeta
    Rus, Horea
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 10 - 11
  • [9] Factors Associated with Glatiramer Acetate Efficacy in Japanese Multiple Sclerosis
    Tanaka, Eizo
    Watanabe, Mitsuru
    Fukumoto, Shoko
    Suezumi, Koki
    Matsushita, Takuya
    Isobe, Noriko
    Masaki, Katsuhisa
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP34 - NP35
  • [10] Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice
    Mitsikostas, Dimos
    Bakirtzis, Christos
    Nikolaidis, Ioannis
    Tsimourtou, Vana
    Kountra, Persa
    Matsi, Stavroula
    Papadimitriou, Alexandros
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (06) : 311 - 322
12345